Merck, Inc.
🇺🇸United States
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-03-30
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 441
- Registration Number
- NCT00106704
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT00106626
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Phase 1
Completed
- Conditions
- Advanced Breast CancerOther Solid Tumors
- First Posted Date
- 2005-03-22
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 103
- Registration Number
- NCT00106145
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
- First Posted Date
- 2005-03-16
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 685
- Registration Number
- NCT00105534
- Locations
- 🇺🇸
Taustine Eye Center, Louisville, Kentucky, United States
🇺🇸Charlotte Eye, Ear, Nose, and Throat, Charlotte, North Carolina, United States
🇺🇸Precision Eye Care, Huntington, New York, United States
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 743
- Registration Number
- NCT00105469
- Locations
- 🇺🇸
Alan Shuster, MD, Jupiter, Florida, United States
🇺🇸Children's Eye Physicians, Littleton, Colorado, United States
🇺🇸Pasco Eye Institute, New Port Richey, Florida, United States
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-03-09
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 179
- Registration Number
- NCT00105157
A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-02-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00104364
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: peginterferon alfa-2b (PEG2b) (SCH 54031)
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT00104052
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1208
- Registration Number
- NCT00103857
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00103714
© Copyright 2025. All Rights Reserved by MedPath